News Releases Keyword search Year None20212020201920182017201620152014201320122011201020092008 11/23/2021 AcelRx Pharmaceuticals Announces the Appointment of Jill Broadfoot to its Board of Directors 11/15/2021 AcelRx Announces $14 Million Registered Direct Common Stock and Warrant Offering 11/15/2021 AcelRx Pharmaceuticals to Acquire Lowell Therapeutics and Reports Third Quarter 2021 Financial Results 11/10/2021 AcelRx to Host Third Quarter 2021 Financial Results Call and Webcast on November 15, 2021 9/10/2021 AcelRx Pharmaceuticals to Participate in Two September Investor Conferences 8/30/2021 Study Results Announced During Award-Winning Presentation on the Effect of Sufentanil Sublingual Tablet on Outpatient Plastic Surgery at the Annual Miami Cosmetic Surgery Event 8/26/2021 Presentation on the Effect of the Administration of Sufentanil Sublingual Tablet on Reducing Post-Operative Recovery Time and Opioid Use in Plastic Surgery at the Annual Miami Cosmetic Surgery Event 8/16/2021 AcelRx Pharmaceuticals Reports Second Quarter 2021 Financial Results 8/9/2021 AcelRx to Host Second Quarter 2021 Financial Results Call and Webcast on August 16, 2021 7/14/2021 AcelRx Enters into Licensing Agreement for DZUVEO® in Europe and In-licensing Agreement for Two Products in the U.S. Current page 1 Page 2 Page 3 Next page next › Last page last » Print Page RSS Feeds
Keyword search Year None20212020201920182017201620152014201320122011201020092008 11/23/2021 AcelRx Pharmaceuticals Announces the Appointment of Jill Broadfoot to its Board of Directors 11/15/2021 AcelRx Announces $14 Million Registered Direct Common Stock and Warrant Offering 11/15/2021 AcelRx Pharmaceuticals to Acquire Lowell Therapeutics and Reports Third Quarter 2021 Financial Results 11/10/2021 AcelRx to Host Third Quarter 2021 Financial Results Call and Webcast on November 15, 2021 9/10/2021 AcelRx Pharmaceuticals to Participate in Two September Investor Conferences 8/30/2021 Study Results Announced During Award-Winning Presentation on the Effect of Sufentanil Sublingual Tablet on Outpatient Plastic Surgery at the Annual Miami Cosmetic Surgery Event 8/26/2021 Presentation on the Effect of the Administration of Sufentanil Sublingual Tablet on Reducing Post-Operative Recovery Time and Opioid Use in Plastic Surgery at the Annual Miami Cosmetic Surgery Event 8/16/2021 AcelRx Pharmaceuticals Reports Second Quarter 2021 Financial Results 8/9/2021 AcelRx to Host Second Quarter 2021 Financial Results Call and Webcast on August 16, 2021 7/14/2021 AcelRx Enters into Licensing Agreement for DZUVEO® in Europe and In-licensing Agreement for Two Products in the U.S. Current page 1 Page 2 Page 3 Next page next › Last page last »
11/23/2021 AcelRx Pharmaceuticals Announces the Appointment of Jill Broadfoot to its Board of Directors
11/15/2021 AcelRx Pharmaceuticals to Acquire Lowell Therapeutics and Reports Third Quarter 2021 Financial Results
8/30/2021 Study Results Announced During Award-Winning Presentation on the Effect of Sufentanil Sublingual Tablet on Outpatient Plastic Surgery at the Annual Miami Cosmetic Surgery Event
8/26/2021 Presentation on the Effect of the Administration of Sufentanil Sublingual Tablet on Reducing Post-Operative Recovery Time and Opioid Use in Plastic Surgery at the Annual Miami Cosmetic Surgery Event
7/14/2021 AcelRx Enters into Licensing Agreement for DZUVEO® in Europe and In-licensing Agreement for Two Products in the U.S.
